LIMK-IN-2, identified by its CAS number 2747216-27-7, is a small molecule inhibitor that specifically targets LIM kinase (LIMK), an enzyme involved in the regulation of actin cytoskeleton dynamics. This compound is of interest in the field of cancer research and other diseases where aberrant cell motility and invasion are critical factors. LIMK-IN-2 functions by inhibiting the phosphorylation of cofilin, a protein that plays a key role in actin filament dynamics, thereby affecting cell migration and proliferation. The compound is characterized by its selective action, which minimizes off-target effects, making it a valuable tool for studying the biological roles of LIMK in various cellular processes. Additionally, LIMK-IN-2 has been evaluated for its potential therapeutic applications, particularly in oncology, where targeting the actin cytoskeleton can influence tumor growth and metastasis. As with any investigational compound, further studies are necessary to fully elucidate its pharmacokinetics, efficacy, and safety profile in clinical settings.

LIMK-IN-2

2747216-27-7: LIMK-IN-2, identified by its CAS number 2747216-27-7, is a small molecule inhibitor that specifically targets LIM kinase (LIMK), an enzyme involved in the regulation of actin cytoskeleton dynamics. This compound is of interest in the field of cancer research and other diseases where aberrant cell motility and invasion are critical factors. LIMK-IN-2 functions by inhibiting the phosphorylation of cofilin, a protein that plays a key role in actin filament dynamics, thereby affecting cell migration and proliferation. The compound is characterized by its selective action, which minimizes off-target effects, making it a valuable tool for studying the biological roles of LIMK in various cellular processes. Additionally, LIMK-IN-2 has been evaluated for its potential therapeutic applications, particularly in oncology, where targeting the actin cytoskeleton can influence tumor growth and metastasis. As with any investigational compound, further studies are necessary to fully elucidate its pharmacokinetics, efficacy, and safety profile in clinical settings.

<p>LIMK-IN-2 (Compound 52), an LIMK inhibitor, has demonstrated potential anti-angiogenic activity by suppressing the cell migration of osteosarcoma and cervical cancer cells [1].</p>

CAS 2747216-27-7

LIMK-IN-2

LIMK-IN-2

Ref: TM-T86811